Alnoor Ramji

Dr. Alnoor Ramji

Clinical Associate Professor, St. Paul’s Hospital

Degrees: B.Sc. (Pharm). MD

Academic position: Clinical Associate Professor, UBC, Dept. Medicine. Division of Gastroenterology.
Appointment St. Paul’s Hospital, Vancouver, BC

St Pauls Hospital

Division of Gastroenterology, Department of Medicine, University of British Columbia

770-1190 Hornby Street

Vancouver BC

telephone 604 688 6332

fax 604 689 2004

Dr. Ramji is a Clinical Associate Professor at the University of British Columbia, practicing at the St. Paul’s hospital site.  He completed his training in Pharmaceutical Sciences at the University of British Columbia.  He thereafter also completed Medical school, Internal medicine and Gastroenterology fellowship training at the University of British Columbia. He undertook a Hepatology fellowship at the University of Toronto with a focus in viral hepatitis.  

Dr. Ramji has been actively involved in clinical research during his Internal Medicine and Gastroenterology training with yearly awards.  Thereafter, Dr. Ramji has been a local principal investigator in over 50 phase IIa, IIb and phase III clinical studies.  The majority of these studies have been in Hepatitis C, including registration studies with Health Canada approvals for regimens.  Other research areas include Hepatitis B, fatty liver disease and cholestasis.  Our centre has lead a number of investigator initiated studies, and collaborations nationally in HCV, HBV and immune liver diseases.  Dr. Ramji has collaborated on the Canadian HCV guidelines for 2012 and 2016.

Dr. Ramji is actively involved in teaching of medical students, residents and Gastroenterology fellows and has received several teaching awards.  He coordinates the Vancouver Liver journal clubs occurring 3-4 times per year, and the annual Liver Forum which is the only provincial liver CME program.  Our centre has a number of CME activities in viral hepatitis and offers preceptorships.  Dr. Ramji has been involved in the core committee for designing numerous national CME accredited programs in viral hepatitis and cholestasis.

Canadian Association of the Study of the Liver (CASL) (Governing board)

Canadian Association of Gastroenterology (CAG)

American Association of the Study for the Study of Liver Diseases (AASLD)

European Association for the Study of the Liver (EASL)

College of Physicians and Surgeons of BC: Committee on the Blood Borne Communicable Disease.

Royal College of Physicians and Surgeons of Canada: Region 1 (BC, Alberta, Yukon and NWT) representative Gastroenterology nucleus committee: 2012 -present

  1. Lee SS, Sherman M, Ramji A. Randomized clinical trial: the efficacy of treatment, guided by a shorter duration of response, using peginterferon alfa-2a plus ribavirin for hepatitis C virus other than genotypes 2 or 3. Aliment Pharmacol Ther. 2012 Jan;35(1):37-47.
  2. Myers, RP, Ramji A, Bilodeau M. et al. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol. 2012 Jun(6):359-75
  3. Pockros P, Jensen D., Tsai N., Taylor R., Ramji A., Cooper C., Dickson R., Tice A., Kulkami R,Vierling J., Najera I., Thommes J. JUMP-C: a randomized trial of mericitabine plus peginterferon alfa- 2a/ribavirin for 24 weeks in treatment-naive HCV genotype 1/4 patients. Hepatology. 2013 Aug;58(2):514-23
  4. Chronic hepatitis C in Western Canada: a survey of practice patterns among Gastroenterologists in Alberta and British Columbia. Pai R, Ramji A, Lee SS, Wong WW, Yoshida EM. Can J Gastroenterol Hepatol. 2014 Jan;28
  5. A randomized controlled trial assessing the effect of prescribed patient position changes during colonoscope withdrawal. Ou G, Kim E, Lakzadeh P, Tong J, Enns R, Ramji A, Whittaker S, Ko HH, Bressler B, Halparin L, Lam E, Amar J, Telford J.Gastrointest Endosc. 2014 Aug;80(2):277-83.
  6. Birden of disease and cost of chronic hepatitis C infection in Canada. Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Can J GastroenterolHepatol. 2014 May;28(5):243-50. Review
  7. Daclatasvir plus peginterefron and ribavirin is non-inferior to peginterferon and ribavirin alone, andreduces the duration of treatment for HCV genotype 2 or 3 infection. Dore GJ, Lawitz E, Hézode C,Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A et al. Gastroenterology. 2015 Feb;148(2):355-366.e1. doi: 10.1053/j.gastro.2014.10.007. Epub 2014 Oct 13.
  8. Rate, delay and predictors of hepatitis C treatment in British Columbia. Yau AH, Lee T, Ramji A, Ko HH. Can J Gastroenterol Hepatol. 2015 Aug-Sep;29(6):315-20. Epub 2015 Apr 15.
  9. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ,Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. JAMA. 2015 May 5;313(17):1736-44. doi: 10.1001/jama.2015.3868.
  10. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial.Lagging M, Brown A, Mantry PS, Ramji A, Weilert F, Vierling JM, Howe A, Gendrano IN 3rd, Hwang P, Zhang B, Wahl J, Robertson M, Mobashery N. J Viral Hepat. 2016 Feb;23(2):80-8. doi: 10.1111/jvh.12464. Epub 2015 Sep 10.
  11. Chronic Hepatitis with Liver Granulomas in a Patient with Granuloma Annulare: A Case Report and Review of the Literature," Case Reports in Gastrointestinal Medicine, vol. 2017, Article ID 8768529, 5 pages, 2017. doi:10.1155/2017/8768529.
  12. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.  Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1821-1830.e6. doi: 10.1016/j.cgh.2016.07.001. Epub 2016 Jul 9. PMID: 27404965
  13. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.  Janjua NZ, Islam N, Wong J, Yoshida EM, Ramji A, Samji H, Butt ZA, Chong M, Cook D, Alvarez M, Darvishian M, Tyndall M, Krajden M. J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684. [Epub ahead of print]
  14. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).  Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall M, Krajden M. EBioMedicine. 2016 Oct;12:189-195. doi: 10.1016/j.ebiom.2016.08.035. Epub 2016 Aug 25.